SSSarah Schaefer

Sarah Schaefer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sarah Schaefer has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of the COVID-19 Pandemic on Candida auris Infections: A Retrospective Analysis in an Academic Medical Center in New York City

    by Sarah Schaefer, Emily Walits, Kalani Thaler, Gopi Patel

    Candida auris, a multidrug-resistant fungus first described in Japan in 2009, has since then spread rapidly around the world. More recently, cases of C. auris have increased substantially, which may have been affected by the strain the COVID-19 pandemic placed on healthcare resources. We describe the epidemiology of C. auris infection and colonization at a tertiary care hospital in New York City before, during, and after the peak of the COVID-19 pandemic and describe our approach to surveillance. We performed a retrospective chart review for all incident cases of C. auris, defined as a patient without a known history of infection or colonization, who had a positive surveillance or clinical culture detected at our institution from 2019 through 2022. Clinical and demographic data were collected using the electronic medical record. Sixty-four incident cases of C. auris were identified. Thirty-four of these were identified by surveillance and 30 by clinical culture. There was a statistically significant increase in the number of cases identified in 2022 compared with 2019, with incidence rates of 2.6 cases per 10,000 admissions in 2019 and 7.8 cases per 10,000 admissions in 2022 (p = 0.002), respectively. The incidence of C. auris colonization or infection increased significantly at our institution during the COVID-19 pandemic suggesting the potential impact the pandemic had on C. auris transmission. Targeted admission surveillance allows for the early identification of C. auris cases and can serve as a valuable tool to combat the increasing transmission of C. auris.


  • Open Access

    Molecular Detection of Candida auris Using DiaSorin Molecular Simplexa® Detection Kit: A Diagnostic Performance Evaluation

    by Juan David Ramírez, Chin Yi Wang, Deandra Bolton, Bernadette Liggayu, Sarah Schaefer, Gopi Patel, Waleed Javaid, Carlos Cordon-Cardo, Adolfo Firpo-Betancourt, Emilia Mia Sordillo, et al.

    Candida auris is a globally emerging fungal pathogen that is associated with healthcare-related infections. The accurate and rapid detection of C. auris is crucial for effective infection prevention, control, and patient management. This study aimed to validate the analytical and diagnostic performance of the DiaSorin Molecular C. auris Detection Kit. The analytical specificity, sensitivity, and reproducibility of the assay were evaluated. The limit of detection (LOD) was determined to be 266 CFU/µL using the ZeptoMetrix Candida auris Z485 strain and standard calibration curves. The assay demonstrated high analytical specificity and showed no amplification against a diverse panel of bacteria and fungi. Clinical validation was conducted using deidentified residual axillary/groin surveillance culture specimens from C. auris culture-positive and culture-negative patients. The DiaSorin Molecular Detection Kit exhibited 100% agreement in sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) when compared to cultures coupled with MALDI-TOF identification. Intra- and inter-reproducibility testing demonstrated consistent and reliable diagnostic performance. This validated assay offers rapid and accurate detection of C. auris, facilitating timely implementation of infection control measures and appropriate patient care. The DiaSorin Molecular C. auris Detection Kit has the potential to aid in controlling the outbreaks caused by this emerging fungal pathogen. Providing a reliable diagnostic tool can contribute to the effective management and containment of C. auris infections in healthcare settings and ultimately improve patient outcomes.


  • Management of Candida auris in an inpatient acute rehabilitation setting

    by Emily Walits, Gopi Patel, Selina Lavache, Rose-Marie Faotto, Adam Pobliner, Sheron Wilson, Sarah Schaefer